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Abstract
Background: The determination of NRAS and BRAF mutation status is a major requirement in the treatment of
patients with metastatic melanoma. Mutation specific antibodies against NRASQ61R and BRAFV600E proteins could
offer additional data on tumor heterogeneity. The specificity and sensitivity of NRASQ61R immunohistochemistry
have recently been reported excellent. We aimed to determine the utility of immunohistochemistry using SP174
anti-NRASQ61R and VE1 anti-BRAFV600E antibodies in the theranostic mutation screening of melanomas.
Methods: 142 formalin-fixed paraffin-embedded melanoma samples from 79 patients were analyzed using
pyrosequencing and immunohistochemistry.
Results: 23 and 26 patients were concluded to have a NRAS-mutated or a BRAF-mutated melanoma respectively. The
23 NRASQ61R and 23 BRAFV600E-mutant samples with pyrosequencing were all positive in immunohistochemistry with
SP174 antibody and VE1 antibody respectively, without any false negative. Proportions and intensities of staining were
varied. Other NRASQ61L, NRASQ61K, BRAFV600K and BRAFV600R mutants were negative in immunohistochemistry. 6 single
cases were immunostained but identified as wild-type using pyrosequencing (1 with SP174 and 5 with VE1). 4/38
patients with multiple samples presented molecular discordant data. Technical limitations are discussed to explain those
discrepancies. Anyway we could not rule out real tumor heterogeneity.
Conclusions: In our study, we showed that combining immunohistochemistry analysis targeting NRASQ61R and
BRAFV600E proteins with molecular analysis was a reliable theranostic tool to face challenging samples of melanoma.
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Background
In the last decade, an improved understanding of the
genetic mutations in melanoma has resulted in a better
knowledge and treatment of this malignant disease. Sev-
eral mutations have been identified that might affect
downstream signaling to increase cell proliferation and
to decrease apoptosis [1]. The mitogen-activated protein
kinase (MAPK) pathway represents a major signaling
cascade driving cell proliferation, differentiation and
survival. This RAS-RAF-MEK-ERK pathway is constitu-
tively activated in melanomas harboring mutations in
oncogenes such as BRAF and NRAS, respectively mu-
tated in about 50 % and 15 % of these tumors [2].
The development of targeted therapies such as selective
BRAF inhibitors has improved the response rate, the
progression-free survival and the overall survival of patients
with metastatic BRAF-mutant melanomas [3–6]. The vast
majority of these serine/threonine protein-kinase mutations
are characterized by the substitution of valine at amino acid
position 600, referred to as BRAFV600. This substitution
leads to a conformational change resulting in constitutive
kinase activity and phosphorylation of downstream targets.
Concerning BRAFV600 mutations, about 85–90 % result in
a substitution of a valine by a glutamic acid (BRAFV600E).
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Other less frequent mutations are: BRAFV600K (ranging
from 5 to 30 %), and BRAFV600R, BRAFV600D, BRAFV600M,
BRAFV600E2, BRAFV600EK601del . Other BRAF hot spots, such
as BRAFL597P and BRAFL597S have incidences less than 1 %.
Response to targeted-therapies concerning the most fre-
quent and rarer mutations have been reported [7–10].
BRAF inhibitors are now the first-line treatment for pa-
tients with unresectable or metastatic melanoma which test
is positive for BRAFV600, in accordance with the recom-
mendations of the health authorities such as the National
Comprehensive Cancer Network and European guidelines
[11, 12].
However, targeting BRAF alone doesn’t definitively
stop disease progression. Other MAPK pathway proteins
such as MEK or NRAS are now the targets of new
agents that are tested in a growing number of clinical
trials. These new agents could increase BRAF-inhibitors’
effectiveness and hinder drug resistance [5, 13–17].
NRAS mutations, were classically reported to be nearly
mutually exclusive to BRAF mutations, at least at the
level of single cells, with only rare recently reported ex-
ceptions [18–22]. The main NRAS-mutations affect the
glutamine at the amino-acid position 61, in 80–90 % of
NRAS-mutant melanomas, with mutations encoded as
NRASQ61R, NRASQ61L, and NRASQ61K. Other less fre-
quent mutation hot spots at amino acid 12 and 13 have
been described [23]. NRASQ61R appears to be the more
frequent NRAS mutation in melanoma with about 40–
67 % to of NRAS mutations [20, 24]. NRAS targeting is a
new field in melanoma treatment and there is no con-
sensus on the NRAS inhibitors to date [25–28]. Never-
theless, the determination of NRAS mutational status is
already of interest in melanoma treatment strategies.
NRAS mutations are common mechanisms of resistance
during treatment with BRAF inhibitors [16, 29]. More
recently, therapeutic trials reported an activity of MEK1/
2 inhibitors in patients with NRAS-mutated melanoma
[30]. Recent data suggested that NRAS mutation in mel-
anoma was also a predictive factor for response to high-
dose interleukin 2 indicating that immunotherapy could
become the first-line treatment for NRAS-mutated meta-
static melanomas, prior to MEK inhibition [31, 32].
For these reasons, the determination of BRAF and
NRAS mutation status appears to be a major criterion
for treatment choices. Validated molecular methods are
available to analyze this status, such as pyrosequencing
technology [33–36]. However, for immunohistochemis-
try (IHC), mainly BRAFV600E detection is yet accepted
[33, 37–43]. To our knowledge, there are only two re-
cent studies concerning anti-NRASQ61R IHC screening
in the literature [19, 20]. This new antibody may provide
additional information on BRAF and NRAS mutational
status, especially concerning potential intratumoral gen-
etic heterogeneity.
This context prompt us, first, to analyze, with pyrose-
quencing and IHC, NRASQ61R, BRAFV600E and other
usual mutations, out of 142 primary and metastatic
melanoma specimens from 79 patients, and to search for
heterogeneity between primary tumors and metastases.
Secondly, we attempted to evaluate the interest of this




We collected 142 melanoma samples from 79 patients
selected from the cases analyzed at the Brest Molecular
Genetic Cancer Platform (France) for theranostic pur-
poses or archived specimens from deceased patients. In
this file, some of the patients were selected because we
had primary and metastatic tumoral samples and some
were included because of their known BRAF and NRAS
mutated status. Patients ongoing treatment with anti-
BRAF target therapy were not included in our study
because BRAF inhibitors can induce acquired NRAS mu-
tations. So NRAS mutations in metastatic tumoral speci-
mens could reflect a treatment-linked selection pressure
and not true primary intra-patient tumoral heterogeneity
(16;29). Cases are summarized in Table 1. The patients’
ages ranged from 17 to 90 years old (average 63.7 years
old). The metastatic tumor sites were lymph nodes, skin,
brain, lung, stomach, mesentery, liver and parotid gland
(see Additional file 1: Table S1 for details). We analyzed
both primary and metastatic formalin-fixed paraffin-
embedded (FFPE) specimens for the same patient, when
different samples were available. Histology slides were
read to confirm the diagnosis and the presence of suffi-
cient tumor tissue for both DNA extraction and pyrose-
quencing and for IHC analysis. The presence and
amount of melanin-pigmentation were quantified at low
magnification using a semi-quantitative scoring: 0 (ab-
sence), 1+ (less than 25 % of pigmented tumor cells), 2+
(25–49 % of pigmented tumor cells), 3+ (50–74 % of
pigmented cells) or 4+ (75–100 % of pigmented tumor
cells). This study was approved by CHRU Brest our
institutional review board (CPP n° DC – 2008 – 214).
DNA extraction
Maxwell 16 CE-IVD system (Promega corporation,
Fitchburg, WI, USA) combined with the Maxwell® 16
Table 1 Summary of the samples available concerning the 79
patients included in the study
Both primary tumor and metastasis 33
More than one metastasis without primary melanoma 5
Only one metastasis without primary melanoma 26
Only primary melanoma 15
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FFPE Tissue LEV DNA Purification Kit (Promega cor-
poration, Fitchburg, WI, USA) was used to isolate DNA
from 3 series of 5 μm sections of macro-dissected tissue




The templates (173 bp of exon 15 of BRAF and 124 bp of
exon 3 of NRAS genes) were amplified using the multiplex-
PCR kit (Qiagen, Courtaboeuf, France) in a 20 μl final vol-
ume containing 2 μl of the tumor DNA. The genotyping of
codons 600 of BRAF and 61 of NRAS was carried out on
PyroMark Q24 system (Qiagen, Courtaboeuf, France) (see
Table 2 for PCR primers sequences and parameters). Nu-
cleotide numbering was done in accordance with HGVS
recommendations (www.hgvs.org/mutnomen). The refer-
ence sequences NM_004333.4 for BRAF gene and
NM_002524.4 for NRAS gene were used for cDNA-based
numbering, i.e. the A of the ATG translational initiation
codon was ascribed as +1. Analyses were considered as non
conclusive (NC) when the pyrosequencing analysis process
failed.
Next generation sequencing
DNA libraries were produced using the Ion Ampli-
Seq™ Cancer Hotspot Panel v2 (Life Technologies,
Saint-Aubin, France) according to the manufacturer’s
instruction. Ten bar-coded (Ion Xpress Barcodes
adapters kit, Life Technologies, Saint-Aubin, France)
tumor DNAs libraries were sequenced simultaneously
on a 316 chip. Sequences were analyzed through the
Torrent suite v4.0 for alignment and SNP-InDels de-
tection to produce BAM and VCF output files. The
data were visualized with Alamut v.2.3 software (Interactive
Biosoftware, Rouen, France) to review ambiguous nucleo-
tide positions.
Immunohistochemistry
Immunohistochemistry for NRASQ61R and BRAFV600E-
mutant were performed using the monoclonal antibodies
N-Ras (Q61R) (clone SP174, Spring Bioscience, Pleasan-
ton, CA, USA) and BRAF V600E (clone VE1, Spring
Bioscience, Pleasanton, CA, USA) at a dilution of 1:100.
Immunohistochemistry was performed on Ventana
Benchmark XT® automated slide preparation system
(Roche Diagnostics, Meylan, France) using two different
revelation kits, OptiView DAB IHC Detection Kit
(Roche Diagnostics, Meylan, France) and ultraView
Universal Alkaline Phosphatase Red Detection Kit
(Roche Diagnostics, Meylan, France). A first line IHC
was performed with ultraView® kit and a second line
IHC was performed with both ultraView® and OptiView®
kits for cases presenting discrepancies in IHC between
samples collecting from the same patient or between
results of molecular mutational status and IHC. The
same protocols were applied to both NRASQ61R and
BRAFV600E IHC. Briefly, IHC was performed on 4 μm
thick sections of the same FFPE material used for muta-
tional testing. A positive control (NRASQ61R mutated
melanoma metastasis or BRAFV600E mutated melanoma
metastasis) was included in each IHC round.
UltraView® Red detection kit was used through Ven-
tana staining procedure included pretreatment with cell
conditioner 1 (pH8) for 60 min, followed by incubation
with diluted antibody at 37 °C for 32 min. Antibody in-
cubation was followed by standard signal amplification
with the Ventana amplifier kit, ultra-Wash, and counter-
staining with one drop of hematoxylin for 12 min and
one drop of bluing reagent for 4 min. Subsequently,
slides were removed from the immunostainer, washed in
water with dishwashing detergent, and mounted.
Optiview® DAB detection kit was used according to
the manufacturer’s instructions.
Immunostaining was interpreted by a single trained
pathologist (AU). As there is no recommended scor-
ing system for the interpretation of this immunohis-
tochemical analysis, we have scored the intensity of
cytoplasmic immunolabelling as negative, “weak posi-
tive” or “strong positive”. In addition, the percentage
of immunostained tumor cells was graded according
to Busam et al.’s scoring system: 0 (negative), 1+
(positive in less than 25 % of tumor cells), 2+
(25–49 % of tumor cells), 3+ (50–74 % of tumor
cells) or 4+ (75–100 % of tumor cells) [38].
Results
Table 3 summarizes the tumors pyrosequencing and
immunohistochemistry profile (NRASQ61 or a BRAFV600
mutation and/or a NRASQ61R or a BRAFV600E positive
immunohistochemistry).
Table 2 Pyrosequencing primers and parameters for genotyping the codons 600-BRAF and 61-NRAS
Gene PCR primers sequence (Forward and Reverse 5′→ 3′) Pyrosequencing primer Nucleotides dispensation order
BRAF Biotin-GCTTGCTCTGATAGGAAAATG GATGGGACCCACTCCATCGAGA GTCTACTGT
CCACAAAATGGATCCAGACA
NRAS ACACCCCCAGGATTCTTACAGA GACATACTGGATACAGCTGGA TCGTATCGAGAG
Biotin-GCCTGTCCTCATGTATTGGTC
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NRAS analysis
In our study, 29.1 % of the patients (23/79) were con-
cluded to have a NRAS-mutated melanoma (17.7 % (14/
79) NRASQ61R, 5.1 % (4/79) NRASQ61L and 6.3 % (5/79)
NRASQ61K). NRASQ61 mutations were detected in 29.5 %
of the samples (38/129) including 23 NRASQ61R
(c.182A>G) mutations (17.8 % of the samples, 60.1 % of
NRASQ61 mutations), 7 NRASQ61L (c.182A>T) mutations
(5.4 % of the samples, 18.4 % of NRASQ61 mutations), 8
NRASQ61K (c.181C>A) mutations (6.2 % of the samples,
21.1 % of NRASQ61 mutations).
All the 23 NRASQ61R-mutant samples detected by py-
rosequencing, had positive immunostaining, with the
NRASQ61R SP174 antibody (from 1+ to 4+, and from
weak to strong) (see Table 3 and Fig. 1a–d. There was
one NRASQ61R-wild-type sample who had positive im-
munostaining (2+, weak). The 7 NRASQ61L-mutant and
the 8 NRASQ61K-mutant detected by pyrosequencing,
were negative for immunostaining, with the NRASQ61R
SP174 antibody.
Sensitivity of IHC with the NRASQ61R SP174 antibody
was 100 % and the specificity was 99.1 %.
The immunostained areas with anti-NRASQ61R anti-
body were 4+ in 13/23 (56.5 %) of the samples including
10 samples with a strong staining intensity. 2/23 (8.7 %),
which had a weak staining, with a 1+ or 2+ grade, were
metastatic samples. In one sample (1/23, 4,3 %), about
two thirds of the tumor surface/cells was weakly stained.
The intensity of staining was strong but concerned less
than 75 % of the tumor surface/cells (inferior to 4+) in
7/23 (30,4 %) of the samples.
A non-specific positive extra-tumoral staining was
observed in 23/142 (16.2 %) samples in monocytes/mac-
rophages cells (Fig. 1m–p). Within those 23 non specific
cases, 7 samples had an adjacent tumor with NRASQ61R
mutation and positive IHC.
BRAF analysis
In our study, 32.9 % of the patients (26/79) were con-
cluded to have a BRAF-mutated melanoma (22.8 % (18/
79) BRAFV600E, 6.3 % (5/79) BRAFV600K and 3.7 % (3/
79) BRAFV600R).
BRAFV600 mutations were found in 30.8 % (37/120) of
the tested samples, including 23 BRAFV600E (c.1799T>A)
mutations (19.2 % of the samples, 62.1 % of BRAFV600
mutations), 8 BRAFV600K (c.1798_1799GT>AA) muta-
tions (6.7 % of the samples, 21.6 % of BRAFV600 muta-
tions), 6 BRAFV600R (c.1798_1799GT>AG) mutations
(5 % of the samples, 16.2 % of BRAFV600 mutations).
Immunohistochemical analysis detected immunolabel-
ling with the anti-BRAFV600E VE1 antibody in the 23
BRAFV600E-mutant samples and in 5 BRAFV600E-wild-
type samples (see Fig. 1e–h, q, r) The BRAFV600K and
BRAFV600R samples showed no staining, as expected.
Sensitivity of IHC detection with BRAFV600E antibody
(clone VE1) was 100 % and specificity was 95.1 %.
The proportion of stained tumor cells, within the
BRAFV600E-mutant samples, was graded 4+ in 17/23
(73.9 %) cases. Among these cases, the staining intensity
varies from strong in 13/17 (76.4 %) to weak in 4/17
(23.5 %) (see Table 3). 2/23 BRAFV600E-mutant samples
(8.7 %) and 1 BRAFV600E-wild-type sample were scored
1+ (Fig. 1i–l). A non-specific positive extra-tumoral
staining of the monocytes/macrophages was observed in
52/142 (36.6 %) of the samples with the anti-BRAFV600E
antibody including 7 samples with adjacent tumor with
BRAFV600E mutation and positive IHC (Fig. 1m–p).
Molecular analysis technical issues and melanin
pigmentation
Molecular analysis of both BRAFV600 and NRASQ61 pro-
file was possible in 119/142 samples. Molecular testing
was conclusive only for either BRAFV600 or NRASQ61 in
1/142 sample and 10/142 samples respectively. Molecu-
lar testing was not conclusive neither for BRAFV600 nor
NRASQ61 in 12/142 samples. The surface of analyzed le-
sions ranged from a few square millimeters to a few
square centimeters and there was no correlation be-
tween the volume of tumor on the slides used for DNA
extraction and the molecular test results. In the samples
with partially and fully conclusive molecular results, the
average proportion of tumor cells was 70.8 % (from 2 to
100 %), and melanin-pigmentation was found in 38.4 %
(50/130) of the cases.
Melanin-pigmentation was reported in less than 25 %
of tumor cells which were 1+ (20.7 %), 25–50 % of
tumor cells 2+ (7.7 %), 50–75 % of tumor cells 3+
(6.2 %) or in more than 75 % of tumor cells 4+ (3.8 %).
Table 3 Immunohistochemistry characteristics of positive
samples and correlation with pyrosequencing mutational status.
Strong / weak describes the intensity of staining and 1+ to 4+
referrers to the percentage of stained tumor cells. WT indicates
wild-type samples according to pyrosequencing data
NRASQ61 pyrosequencing NRASQ61R Non NRASQ61R
IHC NRASQ61R (SP174) Strong Weak Strong Weak
4+ 10 3 0 0
3+ 4 1 0 0
2+ 2 1 0 1 (WT)
1+ 1 1 0 0
BRAFV600 pyrosequencing BRAFV600E Non BRAFV600E
IHC BRAFV600E (VE1) Strong Weak Strong Weak
4+ 13 4 1 (WT) 2 (WT)
3+ 3 1 0 1 (WT)
2+ 0 0 0 0
1+ 0 2 0 1 (WT)
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Within the 23 samples with non-conclusive results of at
least one molecular test, 9 samples showed melanin-
pigmentation. However, less than 25 % of tumor cells
were pigmented among 7 of these 9 samples.
Immunohistochemistry analysis technical issues and
melanin pigmentation
IHC technique was repeated using the high-sensitive
(ultraView Red) and the very high-sensitive (OptiView
Fig. 1 Examples of paired immunohistochemistry and pyrosequencing results. a, b, c, d case #15: primary BRAFV600 wild-type (a) and NRASQ61R
mutated (b) melanoma with strong 4+ immunostaining with SP 174 anti-NRASQ61R antibody using Red (c) or DAB (d) revelation. e, f, g, h case
#18: primary melanoma with BRAFV600 (e) and NRASQ61 wild-type (f) molecular status but presenting strong 4+ staining using VE1 anti-BRAFV600E
antibody (g) and no staining with SP 174 anti-NRASQ61R antibody (h). i, j, k, l case #61: primary BRAFV600 wild-type (i) and NRASQ61K mutated
(j) melanoma having moderate staining using VE1 anti-BRAFV600E antibody (k) and fainter staining with SP 174 anti-NRASQ61R antibody (l). We
concluded in a non-specific ambiguous staining in this sample with both antibodies. Note that red revelation kit as been used here as the faint
melanin-pigmentation could simulate a weak DAB staining. m, n, o, p case #39: BRAFV600 (m) and NRASQ61 wild-type (n) melanoma mesentery
metastasis presenting both strong melanin pigment that could simulate a strong DAB staining and red immunostained cells with both VE1
anti-BRAFV600E (o) and SP 174 anti-NRASQ61R (p) antibodies. We retrospectively concluded that all stained cells were macrophages, without any
evidence of viable tumor cells in this pigmented sample. q, r case #55: BRAFV600E mutated (q) melanoma skin metastasis with strong 4+
immunostaining with VE1 anti-BRAFV600E antibody (r)
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DAB) detection kits for discordant patients only. The re-
sults of these additional testings were identical to the
initial results. There was no difference between Red and
DAB detection systems. Melanin-pigmentation appeared
in some cases to have a more grayish shade than the
brown color of the DAB. However, in the samples with
melanin-pigmentation it was not easy to distinguish be-
tween DAB focal cytoplasmic strong or weak staining
and real melanin-pigmentation of tumor cells. Unlike
DAB, phosphatase alkaline Red detection allowed easier
distinction between a positive staining and melanin-
pigmentation. The melanin-pigmentation was present in
7/23 (30.4 %) of NRASQ61R-mutant samples (i.e. mutated
with pyrosequencing and SP174 antibody immunostain-
ing) and in 12/23 (52.2 %) of the BRAFV600E mutant
lesions (i.e. mutated with pyrosequencing and VE1 anti-
body immunostaining). In contrast, 36/96 (37.5 %) of the
other samples showed at least focal melanin-pigmentation
(1 + and higher) with melanin-pigmentation that could
simulate a DAB staining.
Discrepancies between techniques and samples
For the samples showing non-conclusive molecular ana-
lysis, IHC was interpreted in all these cases. They were
scored as positive with anti-NRASQ61R antibody in 1/13
(7.7 %) and with anti-BRAFV600E antibody in 3/22
(13.6 %).
Among the 38 patients with paired (primary and meta-
static tumors) multiple samples, the genotype deter-
mined by pyrosequencing was discordant in 4 patients
(i.e. inter-lesions): 3 for NRASQ61 (cases #39, #61, #66)
and 1 for BRAFV600 (case #4). Furthermore, cases #39
and #66 had also discordant IHC using anti-NRASQ61R
antibody. 2 other patients presented with a discordant
result using anti-BRAFV600E IHC (cases #48, #61). For
the 4 patients having discordant genotype results (cases
#4, #39, #61 and #66), microsatellite markers confirmed
that the samples originated from the same individual
(data not shown). See Additional file 1: Table S1 for
details.
Discussion
As BRAF inhibition became the reference treatment
of BRAFV600-mutant metastatic melanomas, screening
for BRAFV600 mutations was a major requirement for
an optimal treatment with targeted therapies [44].
NRAS and BRAF mutations have been reported trad-
itionally to be nearly mutually exclusive in a single
tumor with nevertheless rare exceptions of double
mutants [19–21]. As recent data suggested, new more
efficient therapeutic options are becoming available in
NRAS-mutated melanomas such as MEK-inhibitors
and immunotherapy [26, 32]. Beside DNA based tech-
niques, IHC with mutation-specific antibodies are emerging
as a complementary theranostic tool. We evaluated the
combination of novel NRASQ61R and BRAFV600E immuno-
histochemistry as well as pyrosequencing for mutation sta-
tus profiling. In our study, mutations frequencies do not
reflect frequencies encountered in the general melanoma
population. Nevertheless, the numerous NRAS mutated
samples included in our study offers the opportunity to
focus on performances of the new SP174 anti- NRASQ61R
antibody in the melanoma mutational screening.
Molecular analysis
The study by Colomba et al. only reported 1.8 % pyrose-
quencing analysis failure [33]. The relatively high DNA
analysis failure rate (16 %; 23/142) reported in our study
may be explained by the fact that many samples were ar-
chived samples, i.e. did not undergo standardized pre-
analytical steps used for current samples. In our daily
practice, the rate of DNA analysis failure in melanoma
samples is about 3 % and about 1.5 % concerning non-
melanoma samples (unpublished data). The reasons for
DNA analysis failures are not always well-known. Here,
we hypothesized that non-formalin fixatives, late or
over-fixation may explain such failure. A high amount of
melanin-pigmentation, which can play a polymerase
chain reaction-inhibitor role, can explain several amplifi-
cation failures but it is not a single sufficient factor as
the molecular analysis of most pigmented lesions were
conclusive [45].
Immunohistochemistry
IHC detection of NRASQ61R protein with SP174 anti-
body detected all (100 %) the NRASQ61R-mutant samples
(Fig. 1a–d). Our results are consistent with those ob-
tained by Massi et al. and Ilie et al. who have recently re-
ported a sensitivity of 100 % and a specificity of 100 %
with this novel antibody [19, 20]. This antibody showed
performances similar to those published on BRAFV600E
antibody [33, 37–41]. As expected, for other mutations
spots/points, NRASQ61R and BRAFV600E antibodies were
ineffective. These mutations represented 29/142 (20.4 %)
of the samples (17/79 patients, 21.5 %) in this study.
To valid IHC screening, the staining intensity must be
strong enough to be distinguished from an artifact back-
ground or melanin-pigmentation. Even if melanin-
pigmentation was sometimes identified as a grayish pig-
mentation, the red detection was, to our experience
more suitable. Chen et al. have proposed the use of mild
hydrogen peroxide and heating to remove endogenous
melanin in high pigmented samples to improve the
reliability of using anti-BRAFV600E immunohistochemis-
try with DAB staining [46]. Furthermore, melanin-
pigmentation was also present in monocytes/macro-
phages called melanophages. Distinction between a
tumor cell and a melanophage was difficult, e.g. in case
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#39 where the pigmented macrophages could not be dis-
tinguished from DAB-detected immunostained tumor
cells (Fig. 1m–p).
In our study, some lesions were regarded as difficult to
analyze, along with difficulties reported in previous studies
on anti- BRAFV600E IHC whatever chromogens was used
[35, 37, 38, 40–43, 46, 47]. Such ambiguous staining images
may explain the positive IHC scoring of BRAFV600E-wild-
type samples (cases #48 and #61). The positivity of these
two cases was finally considered to be an artifact back-
ground, even more in case #61 where there was also a very
weak staining with anti-NRASQ61R antibody (Fig. 1i–l). In-
terpretation issues of NRASQ61R IHC have also recently
been reported by Ilie et al. who have finally considered a
faint staining as non specific and pointed out the need of a
moderate to strong cytoplasmic staining of at least 60 % of
tumor cells to consider this IHC as positive [19]. Massi
et al. have reported a double mutant BRAFV600E and
NRASQ61R strongly stained with the two anti- BRAFV600E
and anti-NRASQ61R antibodies [20]. Another limitation of
IHC was the interpretation of non-specific staining of
monocytes/macrophages that can be interspersed or clus-
tered, i.e. representing a focal false positive IHC scoring
(Fig. 1m–o). These limitations were similar for both
NRASQ61R and BRAFV600E IHC analysis. In contrast with
the literature, none of our tested samples with necrosis
(some metastatic samples of this study) were misidentified
nor showed altered IHC results. One of the two published
studies to date concerning anti-NRASQ61R antibody have
also reported those issues [19].
Tumor heterogeneity or technical artifacts?
IHC of the specimens gave various intensities and per-
centages of tumor cells in paired primary and metastatic
samples, even though they were positive with pyrose-
quencing. There was no difference in the staining
distribution between primitive or secondary lesions.
Only two cases (cases #66 and #70) seemed to have dis-
cordant primitive and secondary data. In case #66, the
primary sample contained only about 2 % tumor cells
and IHC using antibody targeting NRASQ61R allowed
the identification of the mutated protein whereas pyro-
sequencing failed to identify the mutation. In the same
case, an in-transit metastasis was not stained with
NRASQ61R antibody and was non-conclusive for both
NRASQ61 and BRAFV600 while both lymph node and
skin metastasis were strongly NRASQ61R stained and
mutated. In case #70, the primitive nodular melanoma
was stained with BRAFV600E antibody but non-
conclusive using molecular analysis and the brain
metastasis were BRAFV600E stained and mutated. In
this same case #70, a third lesion (a lymph node
metastasis) was not stained and was non-conclusive
for molecular analysis. Although we cannot rule out
samples inappropriate pre-analytical features which
may explain both IHC false negatives and the failure
of pyrosequencing, these findings are consistent with
real tumoral heterogeneity. Tumoral heterogeneity was
also found in previous studies [19, 20, 38, 48–50].
Nevertheless such heterogeneity did not seem to provide
a major explanation for the discrepancies among a patient’s
samples. Allelic detection limits should also be taken into
account for pyrosequencing false negatives.
The small proportion of tumor cells compared to non-
tumor cells in some samples may be an explanation to this
discrepancy as illustrated above by case #66. Moreover in
case #4, in regard to BRAFV600 mutational status, the lymph
node sample contained only about 10 % of tumor cells on
its histopathological section and was identified as
BRAFV600E-wild-type whereas other samples containing 40
and 70 % of tumor cells showed a clear identification of
BRAFV600E mutation. An additional ultra-deep sequencing
indeed identified 8 of 337 allelic copies (2.3 %) presenting a
c.1799T>A mutation (p.V600E) in the same DNA sample
used for pyrosequencing. This 2.3 % rate of mutated alleles
is undoubtedly bellow pyrosequecing detection threshold.
Consequently, ultra-deep sequencing can be used as an
ancillary identification tool to clarify discrepancies in sam-
ples with a low density of tumor cells. A good correlation
has already been described between anti-BRAFV600E IHC
and ultra-deep sequencing of BRAF in colorectal carcin-
omas and in melanomas. Ihle et al. also reported a 3 % rate
of mutated alleles in a pyrosequencing-negative but IHC
BRAFV600E-positive sample [51, 52]. Mutated tumor cell
sample (intended for DNA extraction) enrichment by
macro- or micro-dissection guided by IHC, may improve
the identification process.
Both tumor and technical features must probably be
considered to explain apparent intratumoral heterogen-
eity in our and previous studies in contrast with others
reporting strong intratumoral homogeneity [37, 53].
How to manage samples with unclear staining?
Analysis of the available literature showed that most
studies report conclusive data on BRAFV600 mutation
status, with only a few that reported non conclusive
cases for molecular and IHC analysis [33, 37]. In the
study by Boursault et al., 3 cases remained unclear in re-
gard to VE1 anti-BRAFV600E immunostaining because of
a faint equivocal brown staining in a BRAFV600E-wild-
type primary melanoma, a BRAFV600E-mutant primary
melanoma and a lymph node BRAFV600K-mutant metas-
tasis [37]. Busam et al. also reported cases of 1+ weak
stained BRAFV600E-mutant lesions with this antibody
but regarded these cases as interpretable positive IHC
cases [38]. On the contrary, Heinzerling et al. and Ihle et
al. regarded a weak staining as negative [9, 51]. On 111
cases, Colomba et al. regarded 8 (7.2 %) cases as
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equivocal for BRAFV600E IHC because of stained macro-
phages, i.e. consistent with our study, and because of a
nuclear staining instead of a cytoplasmic one [33]. In
our study, we did not observe any isolated nuclear stain-
ing. Interpretation criteria for unclear IHC results are
not known [9, 33, 37, 38, 51]. In our study, 6 NRASQ61R-
mutant and 1 NRASQ61-wild-type samples were weakly
stained whereas 7 BRAFV600E -mutant and 5 BRAFV600-
wild-type samples also presented a weak positivity
(Table 3). According to our data, caution must be exer-
cised in case of unclear weak staining. We note that in
our experience there are less numerous unclear cases
with anti-NRASQ61R antibody than with anti-BRAFV600E
one. Massi et al. also have reported moderate to strong
cytoplasmic staining with anti-NRASQ61R antibody in all
their 14 NRASQ61R-mutated samples [20]. Ilie et al. have
required a moderate to strong staining in more than
60 % of tumor cells to consider the anti-NRASQ61R
IHC as positive [19]. In this manner, our faintly stained-
but nevertheless NRASQ61R-mutated samples above
mentioned would have been scored negative in their
study. This difference points out the need of homoge-
neous technical interpretative criteria in this field of
mutation-specific IHC. To our opinion, both molecular
and IHC analysis have to be taken into account to con-
clude in a mutated of not mutated NRAS and BRAF sta-
tus in these samples.
Discrepancies between molecular and IHC analysis
Discrepancies between IHC and molecular data were
also reported within a same sample. As described in our
study, Massi et al. have encountered 3 discordant cases
concerning 2 samples initially considered as NRASQ61R
mutated but non-stained with SP-174 antibody and, at
the opposite, 1 sample positive with this antibody but
wild-type concerning molecular analysis. Additional mo-
lecular genetic analysis have permitted to correct this
discrepancies with the final identification of two
NRASQ61K mutations in the 2 negative samples with
IHC, and with the identification of a NRASQ61R mutation
in the IHC positive sample [20]. Ilie et al. finally have
not encountered discrepant cases by considering high
stringent interpretative cut off (i.e. moderate to strong
staining of at least 60 % of tumor cells) and have re-
ported a specificity of 100 % of anti-NRASQ61R IHC on
the basis of pyrosequencing NRAS mutational status.
The specificity of their assay was diminished to 92 %
taking into account less stringent criteria (i.e. weakly
stained samples corresponding to false positive as NRAS
wild-type or other than NRASQ61R-mutated samples)
[19].
Concerning BRAFV600E mutation, Feller et al. reported
a case of a lesion being positive with IHC and negative
with pyrosequencing analysis of BRAFV600E [40]. Chen
et al. reported a similar case in an esophageal tumor
[46]. These results concurred with those of Marin et al.
for faint to moderate stained lesion [42]. Analyzing cir-
culating melanoma cells, Hofman et al. reported 15 % of
samples to be IHC positive and pyrosequencing negative
[47]. Lade-Keller et al. reported on the one hand, 4/13
cases IHC positive and COBAS® system negative for
BRAF mutation. These authors, on the other hand, re-
ported a case of BRAFV600E mutated melanoma positive
on COBAS® but negative on IHC [35]. Similar IHC nega-
tive and BRAFV600E mutated samples were also reported
by Skorokhod et al. in 2/14 cases and by Ihle et al. who
reported a double mutated codons 600 and 601 tumor,
negative using IHC [43, 51]. Taking into account the
molecular data as a reference, Long et al. found 35 true
positives, 2 false negatives, 57 true negatives and 3 false
positives using anti-BRAFV600E antibody. In Long’s
study, repeated molecular analysis gave the following ex-
planations for the false positive and negative results.
One false negative was reported to be due to an initial
genetic testing: false positive revealed a BRAFK601Q mu-
tation instead of a BRAFV600E one. Three false positives
were also regarded as related to genetic analysis failure.
Finally 2 more BRAFV600E mutated lesions and a third
lesion did not allow molecular detection of the mutation
due to their lacking of enough tumor cells. Nevertheless,
one BRAFV600E mutated case remained IHC negative
without clear explanation [41]. Futhermore, Ihle et al. re-
ported a case of cross reactivity with non BRAFV600E
mutations with an IHC positive sample using VE1 anti-
body whereas molecular analysis showed a BRAFV600R
mutation [51]. Heinzerling reported the same cross re-
activity with a BRAFV600K mutated sample [9]. Finally, in
our study, only one sample (case #18) was strongly and
homogeneously (4+) stained with VE1 anti-BRAFV600E
antibody but wild-type using pyrosequencing without
obvious explanation to this discrepancy to date.
Which place for mutation-specific IHC?
To our opinion, the main advantage of IHC testing is
the accessibility of the test that can be realized in the
same time as histopathological examination. A strong
positive IHC staining quick and sure for NRASQ61R or
BRAFV600E antibodies can accelerate the patient’s thera-
peutic management. Nevertheless, conventional, longer
but wider analysis using molecular techniques must be
realized in case of negative or unclear IHC results. In-
deed, given the performances of these IHC screenings
and the need to identify all the variants of NRASQ61 and
BRAFV600 to guide treatment decision, IHC cannot re-
place molecular analysis, an essential step in melanoma
diagnosis. But IHC can be used as a first-line or a con-
comitant screening tool in the management of every-day
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sample, especially the more challenging ones, as pro-
posed in some studies [19, 54].
Conclusions
The determination of the molecular mutated status of
metastatic melanoma becomes mandatory on the best
way to treat the patient. Intra- and inter-tumor molecu-
lar heterogeneity is a challenge on the avenue to a
molecular diagnostic determination of melanoma. Tech-
nical artifacts must be the first explanation for such an
apparent heterogeneity. As multiple primary melanomas
can exist in a same patient, and as those primary malig-
nant lesions can sometimes be totally regressive and un-
noticed, precaution is required when selecting the
sample to test for molecular status [53]. This is why we
recommend a more exhaustive and systematic analysis
of multiple-tumor specimens for patient’s care and man-
agement rather than a single molecular status [55]. As
showed in our study, technical limitations concern both
molecular and IHC analysis.
SP174 anti-NRASQ61R antibody seemed overall to have
similar performances as VE1 anti-BRAFV600E, with only
some samples remaining ambiguous. To face these chal-
lenges, we suggest a systematic combined IHC analysis
of every sample, using anti-NRASQ61R and anti-
BRAFV600E antibodies and molecular analysis with pyro-
sequencing to complete IHC. We believe that the com-
bination of these techniques and the comparison of their
results may improve the theranostic strategy of melan-
oma by reducing each technique’s drawbacks.
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